BiotechTube

zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

Conditions

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Trial Timeline

Jun 21, 2018 → Sep 30, 2026

NCT ID
NCT03504397

About zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil

zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil is a phase 3 stage product being developed by Astellas Pharma for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03504397. Target conditions include Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer were approved

Approved (5) Terminated (1) Active (14)
✅letrozoleJiangsu Hengrui MedicineApproved
✅FulvestrantAstraZenecaApproved
✅PazopanibNovartisApproved
✅LetrozoleNovartisApproved
✅Trastuzumab emtansineRocheApproved
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03504397Phase 3Active

Competing Products

20 competing products in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
Tadalafil + GemcitabineEli LillyPhase 1
29
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
36
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
zolbetuximabAstellas PharmaPre-clinical
30
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
enfortumab vedotin (EV)Astellas PharmaPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
ASP3082Astellas PharmaPhase 2
42
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
31
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
28